BioNTech (BNTX) CEO Sahin Ugur Sells 79,000 Shares

What Happened

• Sahin Ugur, CEO of BioNTech SE, reported sales of ordinary shares in two open-market transactions. He sold 33,000 shares on 2026-09-21 at $97.81 each for $3,227,720, and 46,000 shares on 2026-09-22 at $100.72 each for $4,633,037 — total proceeds ≈ $7,860,757. These were sales (not purchases), which are generally considered routine disposition rather than a bullish signal.

Key Details

• Transaction dates and prices:
  • 2026-09-21: Sale of 33,000 shares @ $97.81 = $3,227,720
  • 2026-09-22: Sale of 46,000 shares @ $100.72 = $4,633,037
• Total shares sold: 79,000; total proceeds ≈ $7.86M.
• Shares owned after transaction: Not disclosed on this Form 4.
• Footnotes: The ordinary shares are held by Medine GmbH, of which Ugur is the sole shareholder. 106,721 of the shares referenced are held for an individual under a trust where Medine GmbH has voting (but not dispositive) power; Ugur may be deemed to beneficially own those shares.
• Trading plan: Sales were effected under a Rule 10b5-1 trading plan established June 3, 2026.
• Filing timeliness: Form 4 was filed on 2026-09-22; no late filing is indicated.

Context

• These transactions were disposals executed under a pre-established 10b5-1 plan, a common mechanism insiders use to sell shares on an automated schedule. Sales are routine insider activity and do not by themselves indicate management’s view of the company’s prospects.